Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Friday, December 02, 2022
Reaction Biology Corporation announced that the Company has closed on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH ("Bioassay"), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH...
read more
Reaction Biology Corporation has received a subcontract from Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute.
read more
Reaction Biology Corporation (RBC) and PharmaCore Labs (PCL) announced a joint collaboration agreement in China.
read more
Monday, September 24, 2018
A new cell based profiling service for drug discovery from Reaction Biology Corporation (RBC) and Promega Corporation will allow more researchers to better prioritize compounds earlier.
read more
La Loma, Tlalnepantla, Mexico, Real Clean Distribuciones SA de CV is voluntarily recalling all lots four hand sanitizers it manufactured.
read more
Tuesday, January 21, 2025
ReciBioPharm, a division of Recipharm, has been awarded a three-year grant from the Bill & Melinda Gates Foundation (Gates Foundation). The funding will support the global deployment of xRNA Continuous Manufacturing technologies to LMICs.
read more
11 June 2013 - Recipharm AB is pleased to announce that it is working with Vectura Group plc to provide access to its licence for the regulatory dossier of Asmasal® for the Chinese regulatory authorities as part of the Chinese market approval process...
read more
Recipharm has achieved the new ISO 45001 certification at its Wasserburg facility in Germany.
read more
Global contract development and manufacturing organisation (CDMO), Recipharm, announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, ...
read more
Thursday, November 20, 2014
The Pharmaceutical Contract Development and Manufacturing Organisation, Recipharm AB (publ) has acquired Lisbon based CDMO Lusomedicameta Sociedade Técnica Farmacêutica S.A.
read more
Recipharm has completeted the acquisition of OnTarget Chemistry in Uppsala, Sweden. OnTarget Chemistry is a fast growing CRO company with a turnover in 2014 of close to SEK 29 million that is specialized in medicinal chemistry offering synthesis and ...
read more
Recipharm will acquire Sanofi’s contract inhalation drug business and plant in the U.K.
read more
Friday, February 18, 2022
Recipharm announced the acquisition of Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics manufactures oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, ...
read more
Tuesday, October 20, 2026
Recipharm has added pilot-scale manufacturing for high-potency medicines at its Leganés site in Spain, extending the facility’s capabilities from development through clinical production and commercial supply.
read more
Wednesday, December 07, 2016
Recipharm is entering into collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary.
read more